The future of pediatric psychopharmacology.
The future of pediatric psychopharmacology will be a collaborative effort among the public, the federal government, the pharmaceutical industry, and clinical scientists. Clinical scientists and the NIH have initiated the process. The federal regulatory guidelines are in place but may need to be amended further to truly facilitate needed research. The pharmaceutical industry is making efforts to study medications in childhood psychiatric disorders. More new drugs are being tested in humans. Many of the new agents offer the promise of more clinical benefit with milder side effects. The future is indeed promising.
Walkup
J T
JT
Division of Child and Adolescent Psychiatry, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. jwalkup@gwgate1.jhmi.jhu.edu
Cruz
K
K
Kane
S
S
Geller
B
B
D000293:Adolescent; D000296:Adolescent Psychiatry / Q000639:trends*; D000367:Age Factors; D002648:Child; D002665:Child Psychiatry / Q000639:trends*; D002986:Clinical Trials as Topic / Q000639:trends; D004345:Drug Industry / Q000639:trends*; D004346:Drug Information Services / Q000639:trends; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005544:Forecasting; D006801:Humans; D009316:National Institutes of Health (U.S.); D011600:Psychopharmacology / Q000639:trends*; D012109:Research Support as Topic / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration / Q000639:trends